Sionna Therapeutics (Nasdaq: SION) reported that its lead cystic fibrosis candidate failed a Phase IIa proof-of-concept test as an add-on to Trikafta, forcing a strategic reassessment and raising questions about the viability of its nucleotide binding domain 1 (NBD1) stabilizer approach as an add-on to existing standard of care.
The Massachusetts-based company's PreciSION CF Phase IIa proof-of-concept trial of SION-719, an NBD1 stabilizer designed to directly stabilize the structurally defective region of the F508del-mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein, produced a mean placebo-adjusted sweat chloride change of -1.0 mmol/L (p=0.7) when added to Vertex Pharmaceuticals' Trikafta (elexacaftor/tezacaftor/ivacaftor) in 15 adult patients homozygous for F508del. The result was statistically indistinguishable from placebo. Sionna said it will not advance SION-719 as an add-on to standard of care.
The company identified potential confounders in the 14-day crossover study, including higher-than-anticipated variability in individual sweat chloride measurements and differences in Trikafta exposure levels between the SION-719 and placebo periods. Whether these factors meaningfully obscured a real pharmacological effect, or whether the effect is simply absent at the doses and duration tested, remains unresolved. SION-719 was generally well tolerated, with no serious adverse events and no meaningful liver function test signals.
Sionna's entire scientific premise rests on the idea that stabilizing NBD1 — the domain that unfolds at body temperature in F508del-CFTR — can push CFTR function closer to normal levels beyond what approved corrector-potentiator combinations achieve. Trikafta and Vertex's newer Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), which together dominate the CF modulator market, address CFTR processing and gating but do not directly target NBD1 stability. Sionna's differentiation argument depends on that mechanism delivering additive clinical benefit.
The more consequential near-term question is what the Phase IIa failure means for SION-451, Sionna's second NBD1 stabilizer, which the company is developing in proprietary dual combinations rather than as an add-on to Trikafta. The Phase I healthy volunteer trial of galicaftor (SION-2222), a transmembrane domain 1-directed CFTR corrector licensed from AbbVie, in combination with SION-451 met its safety, tolerability, and pharmacokinetic objectives across 120 participants, with SION-451 plus SION-2222 identified as the preferred pairing based on target exposure coverage. The combination was generally well tolerated at once-daily SION-2222 dosing; two participants discontinued in the twice-daily SION-2222 cohorts due to elevated liver function tests and flu-like symptoms, and one discontinued due to rash in the once-daily cohort.